274 results about "Radical radiotherapy" patented technology

The disclosure provides a method of treating a human subject afflicted with lung cancer (e.g., non-small cell lung cancer (NSCLC)) with a programmed death-1 (PD-1) pathway inhibitor (e.g., an anti-PD-1 antibody) and a concurrent chemoradiotherapy (CCRT, e.g., a platinum doublet chemotherapy (PDCT) and a radiation therapy) followed by a combination of a PD-1 pathway inhibitor (e.g., an anti-PD-1 antibody) and a lymphocyte activation gene-3 (LAG-3) antagonist (e.g., an anti-LAG-3 antibody). In some aspects, the method comprises a recovery period that begins upon completion of the treatment with the PD-1 pathway inhibitor and the CCRT and ends at the start of the treatment with the combination of the PD-1 pathway inhibitor and the LAG-3 antagonist.

Systems and methods for guiding radiation therapy including providing particle radiation to a region of interest of a subject and receiving volumetric ionizing radiation acoustic imaging (iRAI) data and ultrasound imaging data from the region of in response the particle radiation. Further, from the iRAI data and the ultrasound imaging, a position of the particle radiation in the region of interest is determined, that position being a treatment position of the particle radiation. Further, the systems and methods determine one or more parameters of the particle radiation for adjusting in response to the determination of the position.

The invention provides radiation sensitive compositions and substrates coated with radiation sensitive compositions wherein the composition comprises a combination of metals and / or metalloid compounds, a functionalized or unfunctionalized acetylenic compound, and other optional ingredients such as amelioration agents. The invention further provides radiation sensitive devices for detection or measurement of radiation comprising substrates coated with these radiation sensitive compositions. The radiation sensitive compositions and devices have applications in dentistry, non-destructive testing, oncology, radiology, and radiotherapy, among others.

Radiotherapy is the most widely used and effective anti-tumor therapy, however it can damage healthy tissues surrounding the tumor. One approach to reducing damage to healthy tissue involves irradiation at dose rates far exceeding those currently used in clinical contexts reduces radiation-induced toxicities while maintaining an equivalent tumor response. This is known as the FLASH effect. The mechanism responsible for reduced tissue toxicity following FLASH radiotherapy (FLASH-RT) is still undetermined; multiple hypotheses have been suggested by linking the high dose rate to rapid oxygen depletion, immune response, reduction of peroxyl radical lifetime, preservation of normal tissue stem cells, etc. While effective, proton therapy is underutilized, contributing to fewer than 2% of all external beam radiation treatments. To overcome this shortcoming, provided are methods which utilize the highest energy layer and a universal range shifter (URS) to facilitate rapid spot arc therapy (RAPIDSPARC™).

The present disclosure relates to the field of radiation therapy and methods, software and systems for treatment planning.

Example methods and systems for kinematic calibration of a treatment couch for radiation therapy are described. In one example, a computer system may generate and send first instruction(s) to cause the treatment couch to move towards each of multiple calibration poses. The treatment couch may be associated with a kinematic model. The computer system may determine multiple measured poses that are associated with the respective multiple calibration poses. Next, the computer system may determine geometric correction data for updating the kinematic model based on the multiple measured poses. The computer system may then generate and send second instruction(s) to update the kinematic model associated with the treatment couch based on the geometric correction data.

A method may include obtaining input data relating to a target treatment plan for performing radiotherapy on a lesion using a radiation device. The input data may include a first target image of the lesion. The method may also include obtaining a segment shape estimation model. The method may also include estimating, based on the segment shape estimation model and the input data, a plurality of target location combinations of the target treatment plan and a plurality of target segment shapes of a collimator of the radiation device. One of the plurality of target location combinations may indicate a location of the collimator relative to the lesion. Each of the plurality of target segment shapes may correspond to one of the plurality of target location combinations.

A pharmaceutical composition for enhancing radiation therapy, containing a fusion protein dimer is disclosed. The fusion protein dimer includes an IL-2 protein and a CD80 protein. A method of radiation therapy for cancer, using the composition is also disclosed. The composition for enhancing radiation therapy may increase the effect of radiation therapy in cancer treatment.

Provided are methods for treating cancer using local administration of certain CpG oligonucleotides (CpG ODN) and systemic administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and / or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-α) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.

The invention provides methods and compositions for treatment of a subject with a glioma. The methods comprise administering a composition comprising Coenzyme Q10 to the subject by continuous intravenous infusion; and administering radiation therapy to the subject. The composition comprising Coenzyme Q10 may be administered to the subject by continuous intravenous infusion for at least 24 hours before the radiation therapy is initiated.

A method for treating liver cancer, in particular in subjects exhibiting homologous recombination deficiency (HRD) positive, comprises the use of hydroxyurea methyl acyl fulvene. The compounds may be administered as monotherapy or in combination with other chemotherapeutic agents and / or radiation therapy.

A system and method for generation and use of radiation outcome prediction (response & side effects) score for patients undergoing radiotherapy for various medical conditions wherein the score is a personalized score, provided by analyzing multiple parameters including the tumor specific, patient specific, gene specific and treatment planning specific parameter(s), during and post therapy.

A radiotherapy system comprising a radiation delivery system 100 and a computer data store configured to store a radiotherapy treatment plan. The radiotherapy treatment plan comprises a plurality of c

The present invention is related to a C—X—C motif chemokine 12 (CXCL12) antagonist for use in a method for treating a tumor in a subject, wherein the method comprises administering to the subject—the C—X—C motif chemokine 12 (CXCL12) antagonist, —a radiotherapy, and—an anti-angiogenic compound, wherein the tumor is a brain tumor.

An automated radiotherapy planning system for generating a deliverable radiotherapy plan (31) for a patient, to be delivered by a predefined radiotherapy delivery system, the system is configured to segment a target volume and one or more organs at risks in a 3D medical image of the patient, generate a prediction of a 3D volumetric dose distribution, generate the deliverable radiotherapy plan (31) and send the deliverable radiotherapy plan (31) to a predefined radiotherapy delivery system for final verification and execution.

A method of treating a tumor in a subject, the method comprises applying a tumor treating field to the tumor at a frequency between approximately 50 kHz and approximately 1,000 kHz; and delivering personalized ultra-fractionated adaptive radiotherapy (PULSAR) regimen.

The present disclosure relates to systems and methods for generating and evaluating radiotherapy treatment plans. In an example, a system may include at least one processor configured to obtain data associated with a three-dimensional (3D) scan of a portion of a patient and at least one optimization objective; generating a set of radiotherapy treatment plans based on the 3D scan; and evaluating each radiation therapy treatment plan in the set of radiation therapy treatment plans based on the kernel function. The kernel function may include a metric evaluation function and a modification function based on the at least one optimization objective. In an example, the at least one processor may be configured to determine a selected radiation therapy treatment plan from a set of radiation therapy treatment plans based on comparing a cost of the selected radiation therapy treatment plan to a cost of each of the radiation therapy treatment plans.

Methods and devices are provided for fabricating and employing patient immobilization devices during radiation treatment procedures. Immobilization devices are provided that include a thin conformal shell configured to conform to an anatomical region of a patient that is to be exposed to radiation during a radiation treatment procedure, with a rigid lattice structure extending outwardly, in an external, beam-facing direction, from the conformal shell. The rigid lattice structure confers structural rigidity to the device, and the thin cellular regions mitigate the impact of the device on a surface dose delivered to the patient or subject. The present mechanical-metamaterial-based immobilization devices incorporate structural features that confer advantageous mechanical properties and radiation transmissive properties when compared with conventional solid or mesh-based immobilization devices used in radiation therapy.

The present application provides a method of treating cancer in an individual, the method comprising administering to the individual a tyrosine kinase inhibitor and an inflammatory agent (such as a TLR agonist, a STING activator, radiation therapy, or an immune checkpoint inhibitor). In some cases, the method involves administering the tyrosine kinase inhibitor when the individual is under inflammatory conditions. In one aspect, the present application provides a method of treating cancer in an individual, the method comprising administering to the individual a) a tyrosine kinase inhibitor and b) an inflammatory agent, optionally comprising intermittently administering the tyrosine kinase inhibitor to the individual.

The present disclosure provides methods of treating or inhibiting cancer, reducing its severity, reducing its risk, or inhibiting its metastasis in an individual with a radiation-activated N-oxide TLR7 / 8 agonist.

Systems, methods, and computer software are disclosed that allow the automatic recalling of imaging parameters from computer memory for controlling an MRI system to perform treatment-day scans of a patient on a treatment couch in a radiotherapy system, prior to treatment. The treatment-day scans can be automatically initialized and the MRI system can then be controlled to perform the treatment-day scans according to the recalled imaging parameters. Reoptimized radiation treatment plan(s) can be automatically generated and predicted doses to anatomical structures of the patient based on the plan(s) can be displayed. Clinicians can be enabled to perform numerous reoptimization tasks simultaneously through parallel workflow interfaces and then a radiation therapy device can be controlled to deliver radiation according to a selected radiation treatment plan.

Provided is a Pt(IV) complex. As a prodrug, the Pt(IV) complex is activated by irradiation to release a Pt(II) complex for the treatment of tumors. Also provided is a pharmaceutical composition including the Pt(IV) complex, and the use of the Pt(IV) complex in the preparation of a drug for treating tumors by means of irradiation activation. Further provided is a kit including the Pt(IV) complex and the description, wherein the description indicates that radiotherapy is performed after administration to treat tumors.

A method for simulating the transport of charged particles in an external magnetic field B is provided, in which the unit direction vector of the charged particle, according to Newton's second law u′(t) = F(u(t), η(t)), includes a force term F, which depends on the unit direction vector u(t) and further nonlinearly depends on the particle's motion variable η(t). According to this method, Newton's second law is solved using an implicit finite difference method, where, over the duration of a time step, the force term is approximated by interpolated values ​​of the unit direction vector and the motion variable, where the interpolation of each quantity is a combination of the values ​​of that quantity at the endpoints t and t+Δt of the time step. This method can be used to calculate the dose when a radiation delivery system 300 delivers a treatment plan P to a patient 310.

The aim of the invention is to allow patients to be individually provided with an effective treatment, the effectiveness of the treatment also involving the minimization of the waiting time of each patient (time to treatment). The invention proposes a method for devising or designing a therapy in the form of a treatment plan prior to a treatment using an interactive navigation on a display device (10). Multiple technologies (A, B,... Z) using irradiating devices (100, 200, 300) are available for selection, among others at least one technology (A) using an irradiating device (100) for emitting protons and at least one technology (B) using an irradiating device (200) for emitting photons. The devised or designed plan defines a plurality of technical settings, which can be set on the irradiating device(s) of the selected technology / technologies, for a person (P), who is to be treated according to the devised or designed plan, with a disease that can be treated by the irradiating device (100, 200, 300). A Pareto front (101; 201; 301) is displayed as a patch in an interactive patch region on the display device (10) for each of at least some of the technologies (A, B,... Z). A number of operating aids (21, 22,...) are displayed in an operating region on the display device (10), each operating aid of the number of operating aids representing a criterion (c1, c2,...) which is improved when a selector (21a, 22a,...) of the respective operating aid is moved or operated in one direction or worsened when the selector is moved or operated in the opposite direction. A fuzzy interval (30, 31, 32) is defined for a target criterion (c1, c2,…), said fuzzy interval also being displayed in a correspondingly represented manner in the interactive patch region and including at least two Pareto fronts (201, 301) for at least two technologies (A, B). The equivalence of two technologies is conveyed to the planner interactively by means of an input of the planner. The two displayed technologies (201, 301) have the same value (c11) for the same target criterion (c1) for the respective patch.

The invention relates to the field of radiotherapy and, more particularly, to the use of a compound based on FMS-like tyrosine kinase 3 ligand (FLT3L) and adoptive cell therapy using dendritic cells in the prevention of cognitive damage associated with radiotherapy.

Timing-based methods, systems, and computer readable mediums for a gated linear accelerator include synchronising a local clock of the linear accelerator with a clock of a patient monitoring system, determining latencies within one or more MR-gated radiotherapy processes and implementing latency based interlocks.

Aspects of the present disclosure are directed to methods and compositions for diagnosing and / or treating a subject having cancer. Certain aspects relate to treatment with a cancer therapy and a YTHDF2 inhibitor or a pharmaceutical composition comprising a cancer therapy and a YTHDF2 inhibitor. In some aspects, the YTHDF2 inhibitor includes an oligonucleotide targeting YTHDF2 mRNA or a small molecule inhibitor of YTHDF2. In some aspects, a subject has been determined to have or to have had resistance to a previous cancer treatment, such as radiotherapy and / or immunotherapy.

A tracking method, a tracking system, and an electronic device are provided. The tracking method includes: acquiring an actual scattering image of a target object at time i, where i is an integer greater than 0, and the actual scattering image is generated according to rays scattered by body tissue where the target object is located; processing the actual scattering image or a reference image corresponding to the actual scattering image with a preset model, and determining a location offset of the target object at the time i according to the processing result; and tracking the target object according to the location offset of at least one time. The preset model is indicative of a location conversion relationship of corresponding pixels in images that are formed before and after the rays are scattered.

Described herein is a graphical user interface that receives a user-specified treatment time value and displays the resultant dose distributions to a target region and / or organs-at-risk (OARs). The dose distributions are depicted as dose volume histograms (DVHs). The user-specified treatment time value may be adjusted as desired and the DVHs for the target region and / or OARs may be correspondingly updated. In some variations, the graphical user interface may comprise bounded DVHs for the target region and / or OARs, where bounds of the DVH represent the range of dose variability between a short treatment time (e.g., T min ) and a long treatment time (e.g., T max ). In some variations, the graphical user interface includes a command button that triggers fluence map optimization using the user-specified treatment time.